Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 4/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.45 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.45 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.45 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.45 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.45 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | PIR | O00625 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297657 | 0.86 | BRAF (0.55) | NEK2CYP3A4BRAFMAP2K1CYP2C9 | |
| SCHEMBL298441 | 0.86 | NEK2 (0.60) | NEK2CYP3A4ROCK1MAP2K1FLT3 | |
| SCHEMBL299283 | 0.85 | BRAF (0.69) | NEK2CYP3A4BRAFMAP2K1CYP2C9 | |
| SCHEMBL298639 | 0.85 | BRAF (0.54) | NEK2CYP3A4BRAFMAP2K1CYP2C9 | |
| SCHEMBL298616 | 0.84 | BRAF (0.57) | NEK2CYP3A4ROCK1BRAFMAP2K1 | |
| SCHEMBL15298809 | 0.84 | BRAF (0.59) | NEK2CYP3A4BRAFMAP2K1CYP2C9 | |
| SCHEMBL19565631 | 0.84 | BRAF (0.61) | NEK2CYP3A4BRAFMAP2K1CYP2C9 | |
| SCHEMBL30866626 | 0.81 | BRAF (0.73) | NEK2CYP3A4BRAFMAP2K1CYP2C9 | |
| SCHEMBL19565640 | 0.81 | BRAF (0.73) | NEK2CYP3A4BRAFMAP2K1CYP2C9 | |
| SCHEMBL299613 | 0.81 | BRAF (0.65) | NEK2CYP3A4BRAFMAP2K1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414764-B2 | Substantially pure vemurafenib and its salts | SHILPA MEDICARE LIMITED | 2019-09-17 | — | — | US | disclosed |
| US-20180334457-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | SHILPA MEDICARE LIMITED (IN) | 2018-11-22 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170320872-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | SHILPA MEDICARE LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | NEK2 325/4885CYP3A4 4851/4885ROCK1 787/4885 |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NEK2 162/4885CYP3A4 4658/4885ROCK1 369/4885 |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NEK2 162/4885CYP3A4 4658/4885ROCK1 369/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NEK2 162/4885CYP3A4 4658/4885ROCK1 369/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NEK2 162/4885CYP3A4 4658/4885ROCK1 369/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NEK2 162/4885CYP3A4 4658/4885ROCK1 369/4885 |
| US-20170320872-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | BRAF, RAF1, NRAS | NEK2 2831/4885CYP3A4 701/4885ROCK1 2275/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NEK2 162/4885CYP3A4 4658/4885ROCK1 369/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NEK2 162/4885CYP3A4 4658/4885ROCK1 369/4885 |
| US-10414764-B2 | Substantially pure vemurafenib and its salts | BRAF, RAF1, NRAS | NEK2 2831/4885CYP3A4 701/4885ROCK1 2275/4885 |
| US-20180334457-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | BRAF, RAF1, NRAS | NEK2 2831/4885CYP3A4 701/4885ROCK1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.